aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.
Market Cap | 53.815 Million | Shares Outstanding | 28.625 Million | Avg 30-day Volume | 249.31 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.46 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -32.345 Million |
Price to Book Value | 1.3041 | Operating Margin | 0.0 | Enterprise Value | 34.448 Million |
Current Ratio | 18.887 | EPS Growth | 0 | Quick Ratio | 18.019 |
1 Yr BETA | 0.8354 | 52-week High/Low | 6.4 / 1.82 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -116.1623 | Altman Z-Score | 8.974 | Free Cash Flow to Firm | -25.231 Million |
Earnings Report | 2023-05-09 |
Please sign in first
none
1.6 Thousand total shares from 1 transactions
16.8 Thousand total shares from 3 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BROADFOOT JILL MARIE CHIEF FINANCIAL OFFICER |
|
0 | 2023-02-16 | 3 |
DENYES NANCY GENERAL COUNSEL |
|
0 | 2023-02-16 | 3 |
SHUKLA SANJAY PRESIDENT AND CEO |
|
0 | 2023-02-16 | 5 |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
6,000 | 2022-04-26 | 1 | |
|
0 | 2020-05-06 | 0 | |
|
0 | 2019-05-08 | 0 | |
|
0 | 2019-05-08 | 0 | |
AMANULLAH ASHRAF SEE REMARKS |
|
No longer subject to file | 2018-05-31 | 0 |
|
0 | 2018-05-15 | 0 | |
|
No longer subject to file | 2018-05-14 | 0 | |
|
11,954 | 2018-03-20 | 0 | |
BLAKE JOHN T SENIOR VICE PRESIDENT, FINANCE |
|
1,932 | 2018-02-06 | 0 |
KING DAVID JOHN CHIEF SCIENTIFIC OFFICER |
|
0 | 2018-02-06 | 0 |
|
0 | 2017-05-09 | 0 | |
|
0 | 2017-05-09 | 0 | |
RAVINDRAN SANUJ K. CHIEF BUSINESS OFFICER |
|
0 | 2017-02-07 | 0 |
MATSUOKA GROVE SEE REMARKS |
|
0 | 2017-02-07 | 0 |
CUBITT ANDREW VP, PRODUCT PROTECTION |
|
0 | 2016-09-13 | 0 |
|
0 | 2016-05-24 | 0 | |
BLACKBURN KELLY VP, CLINICAL AFFAIRS |
|
0 | 2016-03-28 | 0 |
CHRZANOWSKI HOLLY D. SEE REMARKS |
|
0 | 2016-01-27 | 0 |
MCKEW JOHN C. VP, RESEARCH |
|
0 | 2016-01-27 | 0 |
ASHLOCK MELISSA A. SEE REMARKS |
|
0 | 2016-01-27 | 0 |
GRAHAM MARCY SEE REMARKS |
|
0 | 2016-01-04 | 0 |
RAMSDELL FRED VP, IMMUNOLOGY |
|
0 | 2015-10-01 | 0 |
|
No longer subject to file | 2015-05-12 | 0 | |
|
13,414 | 2015-05-12 | 0 | |
|
1,807,820 | 2015-05-12 | 0 | |
|
No longer subject to file | 2015-05-12 | 0 | |
|
No longer subject to file | 2015-05-12 | 0 | |
SOFINNOVA VENTURE PARTNERS IX, L.P. |
|
No longer subject to file | 2015-05-12 | 0 |
POLARIS VENTURE MANAGEMENT CO. V, L.L.C. POLARIS VENTURE PARTNERS V, L.P. POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P. |
|
No longer subject to file | 2015-05-12 | 0 |
|
12,572 | 2015-05-06 | 0 | |
SOFINNOVA VENTURE PARTNERS IX, L.P. |
|
0 | 2015-05-06 | 0 |
CHEREAU FREDERIC COO & PRESIDENT |
|
12,867 | 2015-05-06 | 0 |
WEINER DAVID M. CHIEF MEDICAL OFFICER |
|
5,028 | 2015-05-06 | 0 |
|
27,073 | 2014-01-06 | 0 | |
STEVENSON MARK PRESIDENT & COO |
|
208,866 | 2013-12-18 | 0 |
LUCIER GREGORY T CHIEF EXECUTIVE OFFICER |
|
888,382 | 2012-12-26 | 0 |
|
8,200 | 2012-12-11 | 0 | |
|
1,081 | 2012-10-15 | 0 | |
ANDREWS RONALD ASBURY PRESIDENT, MEDICAL SCIENCES |
|
3,330 | 2012-04-27 | 0 |
LEDDY PETER MICHAEL SVP, GLOBAL HUMAN RESOURCES |
|
27,525 | 2011-11-22 | 0 |
|
1,133 | 2011-08-22 | 0 | |
|
70,000 | 2011-08-01 | 0 | |
BRUST BERND PRESIDENT, MOLECULAR MEDICINE |
|
23,704 | 2011-01-03 | 0 |
MILLER JOHN L PRESIDENT, GENETIC SYSTEMS |
|
98,339 | 2010-12-17 | 0 |
BARTHELEMY NICOLAS PRES, COMMERCIAL OPERATIONS |
|
72,329 | 2010-12-10 | 0 |
COTTINGHAM JOHN A SVP, CHIEF LEGAL OFFICER |
|
53,444 | 2009-12-15 | 0 |
|
13,000 | 2009-05-11 | 0 | |
|
2,747 | 2009-05-08 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-21 17:08:11 -0500 | 2023-02-16 | A | 336,096 | a | 336,096 | direct | ||||||||||
2023-02-21 17:00:23 -0500 | 2023-02-16 | A | 84,023 | a | 84,023 | direct | ||||||||||
2023-02-21 17:04:44 -0500 | 2023-02-16 | A | 84,023 | a | 84,023 | direct | ||||||||||
2023-02-06 19:00:37 -0500 | 2023-02-06 | S | 1,566 | $2.36 | d | 15,460 | direct | -3.6437 | -10.9312 | -23.4818 | 0.0 | 1 | -23.8866 | 28 | ||
2023-02-06 18:57:54 -0500 | 2023-02-03 | M | 10,375 | a | 61,173 | direct | -3.6437 | -10.9312 | -23.4818 | 0.0 | 1 | -23.8866 | 28 | |||
2023-02-06 18:57:54 -0500 | 2023-02-03 | M | 10,375 | d | 31,125 | direct | ||||||||||
2023-02-06 19:00:37 -0500 | 2023-02-03 | M | 3,750 | a | 17,026 | direct | -3.6437 | -10.9312 | -23.4818 | 0.0 | 1 | -23.8866 | 28 | |||
2023-02-06 19:00:37 -0500 | 2023-02-03 | M | 3,750 | d | 11,250 | direct | ||||||||||
2023-02-06 19:03:30 -0500 | 2023-02-03 | M | 2,688 | a | 7,079 | direct | -3.6437 | -10.9312 | -23.4818 | 0.0 | 1 | -23.8866 | 28 | |||
2023-02-06 19:03:30 -0500 | 2023-02-03 | M | 2,688 | d | 8,062 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ATYR PHARMA INC LIFE | 2023-03-24 22:15:03 UTC | 3.8322 | 0.9878 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 21:45:03 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 21:15:03 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 20:45:03 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 20:15:04 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 19:45:03 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 19:15:04 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 18:45:04 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 18:15:03 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 17:45:03 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 17:15:03 UTC | 3.8345 | 0.9855 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 16:45:03 UTC | 3.8322 | 0.9878 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 16:15:03 UTC | 3.8322 | 0.9878 | 300000 |
ATYR PHARMA INC LIFE | 2023-03-24 15:45:03 UTC | 3.8322 | 0.9878 | 300000 |
ATYR PHARMA INC LIFE | 2023-03-24 15:15:03 UTC | 3.8322 | 0.9878 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 14:45:03 UTC | 3.8322 | 0.9878 | 350000 |
ATYR PHARMA INC LIFE | 2023-03-24 14:15:03 UTC | 3.8322 | 0.9878 | 300000 |
ATYR PHARMA INC LIFE | 2023-03-24 13:45:03 UTC | 3.5292 | 1.0408 | 500000 |
ATYR PHARMA INC LIFE | 2023-03-24 13:15:04 UTC | 3.5292 | 1.0408 | 500000 |
ATYR PHARMA INC LIFE | 2023-03-24 12:45:03 UTC | 3.5292 | 1.0408 | 500000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|